WADA prohibited list comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-29. Numbers and descriptions here follow the published literature rather than marketing material.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Rocky Mountain spotted fever, typhus fever and the typhus group, scrub typhus, Q fever, rickettsialpox, and tick fevers caused by Rickettsia, respiratory tract infections caused by Mycoplasma pneumoniae, Lymphogranuloma venereum, trachoma, inclusion conjunctivitis, and uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis, psittacosis, non-gonococcal urethritis caused by Ureaplasma urealyticum, relapsing fever due to Borrelia recurrentis, chancroid caused by Haemophilus ducreyi, plague due to Yersinia pestis, tularemia, cholera, campylobacter fetus infections, brucellosis caused by Brucella species (in conjunction with streptomycin), bartonellosis, granuloma inguinale (Klebsiella species), Lyme disease (Borrelia species). Leptospirosis
The outer layer is continuous with the pretracheal fascia, attaching the gland to the cricoid and thyroid cartilages via a thickening of the fascia to form the posterior suspensory ligament of thyroid gland, also known as Berry's ligament. This causes the thyroid to move up and down with the movement of these cartilages when swallowing occurs.
So, the term "Satsuma ware" came to be associated not with a place of origin but with lower-quality ware created purely for export. Despite this, artists such as Yabu Meizan and Makuzu Kōzan maintained the highest artistic standards while also successfully exporting. From 1876 to 1913, Kōzan won prizes at 51 exhibitions, including the World's fair and the National Industrial Exhibition.
While certain effects of developmental temperature, like body size, are irreversible in ectotherms, others can be reversible. When Drosophila melanogaster develop at cold temperatures they will have greater cold tolerance, but if cold-reared flies are maintained at warmer temperatures their cold tolerance decreases and heat tolerance increases over time. Because insects typically only mate in a specific range of temperatures, their cold/heat tolerance is an important trait in maximizing reproductive output. While the traits described above are expected to manifest similarly across sexes, developmental temperature can also produce sex-specific effects in D. melanogaster adults.
=== Silk Road and early markets === The first marketplace to use both Tor and Bitcoin escrow was Silk Road, founded by Ross Ulbricht under pseudonym "Dread Pirate Roberts" in February 2011. In June 2011, Gawker published an article about the site, which led to "Internet buzz" and an increase in website traffic. This in turn led to political pressure from Senator Chuck Schumer on the US DEA and Department of Justice to shut it down, which they finally did in October 2013 after a lengthy investigation. Silk Road's use of Tor, Bitcoin escrow and feedback systems would set the standard for new darknet markets for the coming years. The shutdown was described by news site DeepDotWeb as "the best advertising the dark net markets could have hoped for" following the proliferation of competing sites this caused, and The Guardian predicted others would take over the market that Silk Road previously dominated. The months and years after Silk Road's closure were marked by a greatly increased number of shorter-lived markets as well as semi-regular law enforcement takedowns, hacks, scams and voluntary closures. Atlantis, the first site to accept Litecoin as well as Bitcoin, closed in September 2013, just prior to the Silk Road raid, leaving users just one week to withdraw any coins. In October 2013, Project Black Flag closed and stole their users' bitcoins in the panic shortly after Silk Road's shut down.
Sources: en.wikipedia.org
== Products and services == Eurogentec has developed three interrelated business units, Life Science Research Products and Services, In Vitro Diagnostics Manufacturing Solutions, and GMP Biomanufacturing.
== Medical uses == Gabapentinoids are approved for the treatment of epilepsy, postherpetic neuralgia, neuropathic pain associated with diabetic neuropathy, fibromyalgia, generalized anxiety disorder, and restless legs syndrome. Some off-label uses of gabapentinoids include the treatment of insomnia, migraine, social phobia, panic disorder, mania, bipolar disorder, and alcohol withdrawal. Existing evidence on the use of gabapentinoids in chronic lower back pain is limited, and demonstrates significant risk of adverse effects, without any demonstrated benefit. The main side-effects include: a feeling of sleepiness and tiredness, decreased blood pressure, nausea, vomiting and also glaucomatous visual hallucinations. In a systematic review analysing data from 5 cohort studies having 10,85,488 patients, use of gabapentinoids (pregabalin and gabapentin) was associated with an increased risks of thrombotic events (deep venous thrombosis and pulmonary thrombo-embolism) as early as three months of use, and with increased risk of cardiovascular events on prolonged use of more than a year duration. Heart failure was not increased with the use of gabapentinoids.
Magnetostratigraphy determines age from the pattern of magnetic polarity zones in a series of bedded sedimentary and/or volcanic rocks by comparison to the magnetic polarity timescale. The polarity timescale has been previously determined by dating of seafloor magnetic anomalies, radiometrically dating volcanic rocks within magnetostratigraphic sections, and astronomically dating magnetostratigraphic sections.
== Prognosis == Addiction is generally understood as a chronic, relapsing condition rather than one resolved in a single episode of care, and long-term outcomes vary widely. A systematic review and meta-analysis of long-term follow-up studies estimated that between 35% and 54% of people with a substance use disorder achieved remission (defined as no longer meeting diagnostic criteria for at least six months) but that this typically occurred only after a mean follow-up of around 17 years, with roughly 7–9% of cases remitting in any given year. Its authors concluded that for a substantial proportion of people the condition behaves more like a long-term than an acute disorder, and argued for treatment models designed around chronicity. Substance use disorders are treatable: there is evidence of clinically significant benefit for medications in opioid, nicotine and alcohol use disorders, for behavioral therapies across all substance use disorders, and for neuromodulation in nicotine use disorder.
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.